STAT
OCTOBER 22, 2024
Novo Nordisk has asked the Food and Drug Administration to bar compounding pharmacies from making copies of its blockbuster weight loss drug semaglutide, arguing that the medication is too complex for the pharmacies to safely make. The FDA still has to make a decision on whether to officially place semaglutide on the lists.
STAT
OCTOBER 23, 2024
Food and Drug Administration to bar compounding pharmacies from making copies of its blockbuster weight loss drug semaglutide, arguing that the medication is too complex for the pharmacies to safely make , STAT reports. … Novo Nordisk has asked the U.S.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Checkup by Singlecare
JUNE 5, 2025
When Zepbound is covered, prior authorization is usually required, and the patient may need to meet clinical requirements such as a BMI of 30 or more or a BMI of 27 or more with a comorbid condition like hypertension or Type 2 diabetes, and documented weight management efforts like a low-calorie diet and increased physical activity.
The Checkup by Singlecare
JUNE 5, 2025
Compounded drugs aren’t usually covered by insurance because they aren’t FDA approved, and the FDA has shared its concerns about compounded GLP-1s like Mounjaro, such as low-quality ingredients, contaminants, or incorrect dosing. You can also log in to your health insurance portal to access policy documents. mL of 5 mg/0.5
STAT
DECEMBER 4, 2024
But documenting the differences between Zepbound and Wegovy in a rigorous way might allow Lilly to make marketing claims about Zepbound’s superior efficacy. A trade group for compounding pharmacies slammed an attempt by Novo Nordisk to convince the U.S.
The Checkup by Singlecare
JUNE 5, 2025
This means the Aetna plan will only cover Mounjaro if the patient’s medical provider provides documented proof that the person meets certain requirements, such as a diabetes diagnosis or concerning blood glucose levels. Prior authorization: Some, if not all, Aetna plans require prior authorization for Mounjaro.
Pharmaceutical Technology
OCTOBER 31, 2022
On receiving approval, the treatment is expected to replace the requirement to use unapproved repackaged oncologic IV bevacizumab from compounding pharmacies for wet AMD treatment. It is also developing registration documents for approvals in Europe, with submission expected in the fourth quarter of this year.
Expert insights. Personalized for you.
143 
Let's personalize your content